⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PLRX News
Pliant Therapeutics, Inc. Common Stock
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
globenewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
globenewswire.com
PLRX
Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
NVO
LLY
BMY
AXSM
JNJ
SNY
BIIB
ABBV
MRK
REGN
GILD
AMGN
AZN
TEVA
BHC
ALKS
VRTX
SRPT
CRIS
NTLA
EDIT
INCY
ACAD
ALNY
CYTK
IONS
EXAS
IDXX
VNDA
SUPN
RGNX
XOM
CVAC
BNTX
ARCT
MRNA
NBIX
ADPT
AVXL
IMUX
PRGS
RDNT
CRDF
ADSK
ANAB
ATRC
CLDX
CPRX
ESPR
EXEL
FGEN
GALT
GRFS
HRMY
IGC
INSM
KODK
LAKE
LCTX
LEXX
LPCN
MESO
MITK
MNKD
MSFT
MYGN
NEO
NVCR
NXPI
OCGN
OMER
ORCL
PACB
PFE
PLRX
PRGO
PSNL
PTGX
QGEN
RARE
ROST
RVMD
SEIC
SIGA
SMCI
SNOW
SOFI
SPRO
TGTX
TNDM
TXG
ULTA
VEEV
VKTX
VRNS
WVE
XRAY
ZBRA
ZNTL
RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
prnewswire.com
BIIB
REGN
GILD
BTE
BROS
BFLY
BCTX
BCRX
BTAI
ALRS
CAPR
CRIS
CYCN
EXAS
FATE
GNTX
HRMY
INCY
IONS
KODK
LAKE
LULU
MRNA
NBIX
NTRA
OCGN
ORGN
PGEN
PLRX
RARE
RGNX
RXRX
SAVA
SGMO
SNOW
SRPT
STEM
TGTX
TLSA
TXG
VRTX
ZETA
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
globenewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
globenewswire.com
PLRX
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
prnewswire.com
PLRX